Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Seventy-one isolates of Cryptococcus neoformans and 5 isolates of Prototheca spp. were tested for in vitro susceptibility against amphotericin B alone and against the combination of amphotericin B with each clinically relevant concentration of flucytosine (5-FC) and rifampin by broth dilution methods. The combinations of amphotericin B and rifampin produced greater effect on reduction of the minimal inhibition concentration (MIC) of amphotericin B than did either drug used individually. Flucytosine combined with amphotericin B produced little or no reduction of the MIC compared with amphotericin B alone.
Srimuang
S
S
Research Center, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.
Prariyachatigul
C
C
Chaiprasert
A
A
Rungsipanuratn
W
W
Tanphaichitra
D
D
D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000302:isolation & purification; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011525:Prototheca / Q000187:drug effects* / Q000302:isolation & purification; D012680:Sensitivity and Specificity
D000935:Antifungal Agents; D000666:Amphotericin B; D005437:Flucytosine